28 January 2023 - AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.

In 2016, a blockbuster drug called Humira was poised to become a lot less valuable.

The key patent on the best selling anti-inflammatory medication, used to treat conditions like arthritis, was expiring at the end of the year. Regulators had blessed a rival version of the drug, and more copycats were close behind. The onset of competition seemed likely to push down the medication’s $50,000/year list price.

Instead, the opposite happened.

Read New York Times article